18,262 results match your criteria Mesothelioma


Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.

Multimed Man Cardiothorac Surg 2020 Jul 6;2020. Epub 2020 Jul 6.

Department of Cardio-Thoracic Surgery Erasmus University Medical Center Rotterdam The Netherlands.

Malignant pleural mesothelioma is a disease of the pleural cavity that is strongly associated with asbestos exposure. In most cases it carries a poor prognosis. Patients often present with respiratory symptoms, caused by pleural effusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1510/mmcts.2020.038DOI Listing

Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.

J Thorac Cardiovasc Surg 2020 May 29. Epub 2020 May 29.

Division of Renal Medicine, Brigham and Women's Hospital, Boston, Mass; Section of Nephrology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Mass. Electronic address:

Objectives: Cytoreductive surgery with hyperthermic intraoperative chemotherapy with cisplatin has been used successfully to treat malignant pleural mesothelioma, a highly aggressive malignancy that is rapidly fatal in most cases. We hypothesized that the combination of ischemic injury with nephrotoxic injury from cisplatin would result in high rates of acute kidney injury.

Methods: We conducted an observational study in 503 patients to study the risks and outcomes of acute kidney injury after surgical resection of malignant pleural mesothelioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2020.05.033DOI Listing

Occupational cohort study of asbestos-cement workers in a contaminated site in Sicily (Italy).

Epidemiol Prev 2020 Mar-Jun;44(2-3):137-144

Department of Environment and Health, Istituto Superiore di Sanità, Rome (Italy).

Objectives: to analyse the asbestos-related diseases risk among the former workers of Sacelit asbestos-cement plant, operating in San Filippo del Mela (Sicily: 1958- 1993).

Design: cohort study.

Setting And Participants: 228 subjects were employed in Sacelit from 1958 to 1993. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19191/EP20.2-3.P137.036DOI Listing

[Five Years PLEURATUMOR Register of the German Society of Thoracic Surgery].

Zentralbl Chir 2020 Jul 6. Epub 2020 Jul 6.

Abteilung für Thoraxchirurgie, Universitätsklinikum Regensburg, Deutschland.

Background: Since 01.01.2015, the nationwide "PLEURATUMOR Register of the German Society of Thoracic Surgery (DGT)" has documented the most relevant parameters of patients with primary and secondary malignant pleural diseases receiving thoracic surgery in Germany. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1178-1355DOI Listing

Quantitative Tc Labeling Kit for HYNIC-Conjugated Single Chain Antibody Fragments Targeting Malignant Mesothelioma.

Bioconjug Chem 2020 Jul 6. Epub 2020 Jul 6.

Department of Anesthesia, University of California, San Francisco, California 94143, United States.

Single chain antibody fragment (scFv) is a promising agent for imaging and targeted therapy. The objective of the study is to evaluate a kit formulation for Tc labeling of scFv for tumor imaging. The scFv was engineered to contain a cysteine tag to accommodate the specific conjugation of HYNIC and subsequent Tc labeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.0c00319DOI Listing

Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis.

Scand J Work Environ Health 2020 Jul 6. Epub 2020 Jul 6.

Health Sciences, Exponent, Inc., 149 Commonwealth Drive, Menlo Park, California, 94025, USA.

As the first case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis (mTVT), the paper by Marinaccio et al (1) is potentially an important epidemiologic contribution. A careful review of the paper, however, raises a number of methodological issues. Any case-control study can be viewed as being nested within a conceptual cohort, with controls being sampled from the at-risk cohort as cases arise over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5271/sjweh.3909DOI Listing

Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.

Clin Lung Cancer 2020 May 23. Epub 2020 May 23.

Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland; Individualized Drug Therapy Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Introduction: Malignant pleural mesothelioma (MPM) is a fatal malignancy strongly associated with previous asbestos exposure. Overall survival remains dismal, partly owing to poor response to available treatment. The aims of this study were to evaluate diagnostic accuracy in a group of patients with MPM with an unusually long survival time and to assess the factors related to this prolonged survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.020DOI Listing

PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.

Clin Lung Cancer 2020 May 22. Epub 2020 May 22.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.012DOI Listing

Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.

Lung Cancer 2020 Jun 21;146:318-326. Epub 2020 Jun 21.

Clinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, Via Conca 71, 60126, Ancona, Italy. Electronic address:

Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is a matter of debate. We aimed to clarify whether MPM patients with loss of BAP1 expression have better overall survival (OS) compared to BAP1 positive patients.

Methods: BAP1 immunohistochemical staining of tumor samples from 60 MPM patients treated at our institution with first-line chemotherapy was evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.06.024DOI Listing

Appendageal Tumors and Tumor-Like Lesions of the Testis and Paratestis: A 32-Years of Experience at a Single Institution.

Hum Pathol 2020 Jun 30. Epub 2020 Jun 30.

Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address:

The testicular hilum and paratestis contain several embryologically diverse anatomic structures, including the spermatic cord, tunica vaginalis, epididymis, rete testis, and several other embryonic remnants. Several benign and malignant lesions arise from these morphologically distinct structures, and, due to their proximity, it is challenging to classify and subsequently stage these tumors. Herein, we conducted a retrospective review of the paratesticular appendageal and rete testis tumors and tumor-like lesions diagnosed at our department from 1985 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2020.06.006DOI Listing

Tumor Treating Fields - behind and beyond inhibiting the cancer cell cycle.

CNS Neurol Disord Drug Targets 2020 Jul 2. Epub 2020 Jul 2.

Department of Neurosurgery, Inselspital, Bern University Hospital, Bern. Switzerland.

The unmet need for a safe treatment that significantly improves the overall survival as well as the quality of life of patients with brain tumors has urged researchers to work out new treatment modalities. About 15 years ago it was shown that alternating electric fields significantly impair the growth of cancer cells. Recently, this potentially revolutionary approach called Tumor Treating Fields (TTFs) has been FDA-approved for treatment of glioblastoma as well as mesothelioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871527319666200702144749DOI Listing

Pleural effusions and pneumothorax: Beyond simple plumbing: Expert opinions on knowledge gaps and essential next steps.

Respirology 2020 Jul 1. Epub 2020 Jul 1.

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.

Pleural diseases affect millions of people worldwide. Pleural infection, malignant pleural diseases and pneumothorax are common clinical challenges. A large number of recent clinical trials have provided an evidence-based platform to evaluate conventional and novel methods to drain pleural effusions/air which reduce morbidity and unnecessary interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.13881DOI Listing

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.

Sci Transl Med 2020 Jul;12(550)

Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

LMB-100 is an immunotoxin targeting the cell surface protein mesothelin, which is highly expressed in many cancers including mesothelioma. Having observed that patients receiving pembrolizumab off protocol after LMB-100 treatment had increased tumor responses; we characterized these responses and developed animal models to study whether LMB-100 made tumors more responsive to antibodies blocking programmed cell death protein 1 (PD-1). The overall objective tumor response in the 10 patients who received PD-1 inhibitor (pembrolizumab, 9; nivolumab, 1) after progression on LMB-100 was 40%, and the median overall survival was 11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaz7252DOI Listing

Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.

Clin Lung Cancer 2020 May 23. Epub 2020 May 23.

Department of Radiation Oncology, New York Proton Center, New York, NY. Electronic address:

Background: Despite accounting for a minority of malignant pleural mesothelioma (MPM) diagnoses, females may experience differential survival relative to males. It is unclear if there are gender-based differences in receipt of treatment or disease-related outcomes for patients with MPM. We therefore utilized the National Cancer Database (NCDB) to assess patterns-of-care and overall survival (OS) among patients with MPM by gender. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.021DOI Listing

[Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad].

Laeknabladid 2020 07;106(7):344-348

Department of Abdominal Surgery, Landspitali University Hospital and Faculty of Medicine, University of Iceland.

Background: Peritoneal carcinomatosis is a known complication of colorectal cancer and has long been considered very difficult to manage. The survival has been reported to be under two years after systemic chemotherapy with or without palliative surgery. The most recent method of treatment is compiled of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and has been suggested to significantly increase survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17992/lbl.2020.0708.590DOI Listing

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.

Oncologist 2020 Jul 1. Epub 2020 Jul 1.

Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Lessons Learned: Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes.

Background: Malignant mesothelioma is an aggressive disease for which few effective therapies are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0610DOI Listing

TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.

Pharmaceuticals (Basel) 2020 Jun 28;13(7). Epub 2020 Jun 28.

Department of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph13070137DOI Listing

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.

Biomolecules 2020 Jun 28;10(7). Epub 2020 Jun 28.

Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.

Mesothelin (MSLN) is a cell surface glycoprotein normally expressed only on serosal surfaces, and not found in the parenchyma of vital organs. Many solid tumors also express MSLN, including mesothelioma and pancreatic adenocarcinoma. Due to this favorable expression profile, MSLN represents a viable target for directed anti-neoplastic therapies, such as recombinant immunotoxins (iToxs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom10070973DOI Listing

A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT.

Clin Nucl Med 2020 Jun 25. Epub 2020 Jun 25.

From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University.

Localized malignant mesothelioma is rare. The prognosis is generally more favorable for this condition than for diffuse malignant mesothelioma. An elderly woman recently complained of abdominal pain, fever, and weight loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003158DOI Listing

Mortality among US military participants at eight aboveground nuclear weapons test series.

Int J Radiat Biol 2020 Jun 30:1-64. Epub 2020 Jun 30.

Risk Assessment Corporation, Neeses, South Carolina, USA.

: Approximately 235,000 military personnel participated at one of 230 U.S. atmospheric nuclear weapons tests from 1945 through 1962. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09553002.2020.1787543DOI Listing

Predictors of filing claims and receiving compensation in malignant mesothelioma patients.

Health Policy 2020 Jun 10. Epub 2020 Jun 10.

Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Italian Workers' Compensation Authority (INAIL), Via Stefano Gradi, 55, 00143 Rome, Italy.

Although the predominant occupation origin of mesothelioma is well known, determinant factors involved in filing compensation are scarcely investigated. A linkage between incident mesothelioma cases collected by Italian mesothelioma register (ReNaM) and compensation claims and assignment by Italian national insurance Institute (INAIL) has been conducted for cases diagnosed in the period 2010-2015 and occupational exposure to asbestos. Logistic regression models and decision tree models have been used to identify demographic, diagnostic and anamnestic factors significant for filing and receiving compensation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healthpol.2020.06.005DOI Listing

Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.

Ther Adv Respir Dis 2020 Jan-Dec;14:1753466620935770

Department of Oncology, Fourth Medical Center of Chinese PLA General Hospital, No. 51 Fucheng Road, Haidian District, Beijing, 100037, China.

rearranged malignant pleural mesothelioma (MPM) is rare and its responses to anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and lorlatinib, remain unexplored. In this case report, we describe a patient with -rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively. He had remarkable response evaluated as partial response on both regimens lasting approximately 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753466620935770DOI Listing

Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells.

Acta Cytol 2020 Jun 29:1-5. Epub 2020 Jun 29.

Department of Pathology, Institute of Pathology and Medical Genetics, University Hospital of Basel, Basel, Switzerland,

Introduction: In effusion cytology, mesothelial cells can occasionally present with striking intracytoplasmic accumulation of rod- and crystal-like cytoplasmic lamellar inclusions (LIs). Their nature and function are poorly understood, and their diagnostic relevance is unknown.

Objective: The aim of this study was to explore the nature of LIs in mesothelial cells and determine their prevalence and diagnostic utility in routine practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508757DOI Listing

What are the psychological effects of mesothelioma on patients and their carers? A scoping review.

Psychooncology 2020 Jun 28. Epub 2020 Jun 28.

Division of Nursing and Midwifery, University of Sheffield, Sheffield, UK.

Objective: Despite recent advances in research, malignant mesothelioma remains an incurable and devastating disease, typically bringing shock and emotional distress to patients and carers. Little research has addressed the psychological impact on either group. This scoping review examines the current state of evidence on the psychological effects of mesothelioma on patients and carers, and identifies areas for further research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.5454DOI Listing

Editorial: Emerging Therapies for Malignant Mesothelioma.

Front Oncol 2020 12;10:939. Epub 2020 Jun 12.

Department of Thoracic Oncology, Netherland Cancer Institute, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00939DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304317PMC

Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.

J Thorac Oncol 2020 Jul;15(7):e113-e116

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Labex IGO, Immunology Graft Oncology, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.04.011DOI Listing

Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.

J Thorac Oncol 2020 Jul;15(7):e111-e113

Department of General Thoracic Surgery, Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.03.007DOI Listing

Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma.

Arch Pathol Lab Med 2020 Jun 26. Epub 2020 Jun 26.

From the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Context.—: Distinguishing pulmonary sarcomatoid carcinoma from pleural sarcomatoid mesothelioma is challenging because of overlapping histology, immunophenotype, and clinical features. Reliable immunohistochemical markers to aid in this distinction would be very valuable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2019-0647-OADOI Listing

Medical thoracoscopy in the diagnosis of pleural disease: a guide for the clinician.

Expert Rev Respir Med 2020 Jun 26. Epub 2020 Jun 26.

Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Interventional Pulmonology , 2220 Pierce Avenue, Suite 1710, Nashville, TN 37232, USA.

Introduction: Developing a feasible and accurate means of evaluating pleural pathology has been an ongoing effort for over 150 years. Pleural fluid cellular and biomarker analyses are simple ways of characterizing and uncovering pathologic entities of pleural disease. However, obtaining samples of pleural tissue has become increasingly important. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2020.1788940DOI Listing

Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.

Pathol Int 2020 Jun 24. Epub 2020 Jun 24.

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

We report a case with a rare combination of synchronous lung adenocarcinoma and bilateral malignant pleural mesotheliomas in a 70-year-old male without asbestos exposure. He metachronously developed peritoneal malignant mesothelioma, intrahepatic cholangiocarcinoma, urothelial carcinoma of the bladder and prostatic adenocarcinoma. Immunohistochemistry revealed complete loss of BAP1 expression in all seven lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12977DOI Listing

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.

Front Oncol 2020 3;10:777. Epub 2020 Jun 3.

Department of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, Netherlands.

Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in MPM. Unfortunately, clinical studies that investigate the effectivity of checkpoint inhibitor (CI) treatment failed to improve clinical outcome over current applied therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283907PMC

Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome.

Intern Med 2020 Jun 23. Epub 2020 Jun 23.

Department of Clinical Laboratory, Hiroshima-Nishi Medical Center, Japan.

A 30-year-old man was admitted to our hospital because of pain in his proximal extremities. The pain mimicked polymyalgia rheumatica (PMR) and it temporarily improved by a low dose of glucocorticoids, but his symptoms relapsed many times. After six years of glucocorticoid treatment, he developed abdominal pain and ascites, for which he was diagnosed with malignant peritoneal mesothelioma (MPM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4809-20DOI Listing

Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.

J Immunother Cancer 2020 Jun;8(1)

Université de Nantes, CNRS, INSERM, CRCINA, F-44000 Nantes, France

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The tumor microenvironment content, particularly the presence of macrophages, was described as crucial for the development of the disease. This work aimed at studying the involvement of the M-CSF (CSF-1)/IL-34/CSF-1R pathway in the formation of macrophages in MPM, using samples from patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2019-000182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319783PMC

Role of inflammation in the malignant transformation of pleural mesothelial cells induced by multi-walled carbon nanotubes.

Nanotoxicology 2020 Jun 23:1-21. Epub 2020 Jun 23.

Department of Hygienic Toxicology and Center for Evaluation of Drug Safety, The Navy Military Medical University, Shanghai, PR China.

Multi-walled carbon nanotubes (MWCNTs) are one of the most widely used types of novel nano-fiber materials. The aim of this study was to establish an experimental system based on actual exposure dosage and environments and explore the roles and mechanisms of inflammation in the malignant transformation of pleural mesothelial cells induced by MWCNTs after low doses and long-term exposure. Here, we established an system by co-culturing macrophages and mesothelial cells and exposing these cells to high aspect ratio MWCNTs (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17435390.2020.1777477DOI Listing

Absence of mesothelioma risk maintained in an expanded international cohort of cosmetic talc miners and millers.

Inhal Toxicol 2020 May 22;32(6):257-264. Epub 2020 Jun 22.

Cardno ChemRisk, Pittsburgh, PA, USA.

Based on novel information for the Vermont cosmetic talc miner/miller cohort, including a reported case of mesothelioma, we sought to update our prior pooled statistical power analyses of mesothelioma incidence among European cosmetic talc miners/millers. With the inclusion of the Vermont cohort, we expanded our pooled analysis by 17,170 person-years of observation. Cosmetic talc miner/miller cohort studies conducted in Italy, Norway, France, Austria, and Vermont were pooled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08958378.2020.1781304DOI Listing

Predicting cancer using supervised machine learning: Mesothelioma.

Technol Health Care 2020 Jun 19. Epub 2020 Jun 19.

Background: Pleural Mesothelioma (PM) is an unusual, belligerent tumor that rapidly develops into cancer in the pleura of the lungs. Pleural Mesothelioma is a common type of Mesothelioma that accounts for about 75% of all Mesothelioma diagnosed yearly in the U.S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/THC-202237DOI Listing

RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.

Pract Radiat Oncol 2020 Jun 17. Epub 2020 Jun 17.

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Background And Purpose: Treatment planning for malignant pleural mesothelioma (MPM) is a challenging task due to the relatively large size of the target and the need to spare critical organs that overlap with or are within the target volume. We aimed to develop a knowledge-based-model (KBM) using RapidPlan for patients with two intact lungs.

Materials And Methods: Data from 57 patients treated with volumetric modulated arc therapy (VMAT) were chosen for training the dose estimation model at a single dose level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2020.06.003DOI Listing

Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series.

Surg Oncol 2020 Jun 25;33:96-99. Epub 2020 Jan 25.

Program in Peritoneal Surface Malignancies, MedStar Washington Hospital Center, Washington, DC, USA.

Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a disease in transition. Two decades ago this cancer had a median survival of 1 year. Recent reports in selected patients show a 5-year survival of 70% and median survival not reached at 10 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suronc.2020.01.009DOI Listing

Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review.

Int J Mol Sci 2020 Jun 17;21(12). Epub 2020 Jun 17.

Clinical Institute, Aalborg University Hospital, 9000 Aalborg, Denmark.

Malignant mesothelioma (MM) is mainly caused by air-born asbestos but genetic susceptibility is also suspected to be a risk factor. Recent studies suggest an increasing number of candidate genes that may predispose to MM besides the well-characterized BRCA1-associated protein-1 gene. The aim of this review is to summarize the most important studies on germline mutations for MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21124327DOI Listing

Psychological Distress after a Diagnosis of Malignant Mesothelioma in a Group of Patients and Caregivers at the National Priority Contaminated Site of Casale Monferrato.

Int J Environ Res Public Health 2020 Jun 17;17(12). Epub 2020 Jun 17.

Department of Psychology, University of Turin, 10123 Turin, Italy.

Background: Patients of malignant mesothelioma (MM) and their caregivers face significant physical and psychological challenges. The purpose of the present study is to examine the emotional impact after the diagnosis of MM in a group of patients and familial caregivers in a National Priority Contaminated Site (NPCS).

Methods: A sample of 108 patients and 94 caregivers received a sociodemographic/clinical questionnaire, the Beck Depression Inventory II, the Davidson Trauma Scale, the Coping Orientation to the Problems Experienced-New Italian Version, and the Defense style questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph17124353DOI Listing

A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT.

Clin Nucl Med 2020 Jun 17. Epub 2020 Jun 17.

From the Department of Radiology.

A 62-year-old woman was referred for cough and lower abdominal pain. F-FDG PET/CT showed strong uptake not only in the left lung mass and hilar and mediastinal lymph nodes, but also a huge lower abdominal mass. All lesions were initially thought to be multiple metastases because bronchial biopsy of the lung mass showed poorly differentiated adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003129DOI Listing

MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.

JCI Insight 2020 Jun 18;5(12). Epub 2020 Jun 18.

"Marianthi Simou Laboratory", 1st Department of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens, School of Medicine, Evangelismos Hospital, Athens, Greece.

Oxidative stress and inadequate redox homeostasis is crucial for tumor initiation and progression. MTH1 (NUDT1) enzyme prevents incorporation of oxidized dNTPs by sanitizing the deoxynucleoside triphosphate (dNTP) pool and is therefore vital for the survival of tumor cells. MTH1 inhibition has been found to inhibit the growth of several experimental tumors, but its role in mesothelioma progression remained elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.134885DOI Listing

Impact of Hospital Volume on Outcomes of Elective Pneumonectomy in the United States.

Ann Thorac Surg 2020 Jun 15. Epub 2020 Jun 15.

Cardiovascular Outcomes Research Laboratories, University of California, Los Angeles; Division of Cardiac Surgery, Department of Surgery, University of California, Los Angeles. Electronic address:

Background: Despite advances in surgical technique and perioperative management, pneumonectomy remains associated with significant morbidity and mortality. The purpose of this study was to examine the impact of annual, institutional volume of anatomic lung resections on outcomes following elective pneumonectomy.

Methods: We evaluated all patients who underwent elective pneumonectomy from 2005 to 2014 in the National Inpatient Sample. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2020.04.115DOI Listing

Asbestos-related diseases.

Int J Tuberc Lung Dis 2020 Jun;24(6):562-567

School of Medicine, Curtin University of Technology, Bentley, WA, Australia.

Knowledge of asbestos-related diseases has been accumulating for over one hundred years as the industrial value of asbestos was recognised for the strength of its fibres and their resistance to destruction, resulting in increasing production and use until the multiple health effects have become apparent. Deposition in the lung parenchyma results in an inflammatory/progressively fibrotic response, with impaired gas exchange and reduced lung compliance ('asbestosis'), causing progressive dyspnoea and respiratory failure for which only palliation is indicated, although anti-fibrotic agents used for idiopathic usual interstitial pneumonitis remain to be evaluated. Benign pleural effusion, diffuse pleural fibrosis (occasionally with associated rolled atelectasis) and pleural plaques are the non-malignant pleural diseases that result from fibres reaching the pleura. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5588/ijtld.19.0645DOI Listing

Global use of asbestos - legitimate and illegitimate issues.

Authors:
Arthur L Frank

J Occup Med Toxicol 2020 15;15:16. Epub 2020 Jun 15.

Dornsife School of Public Health of Drexel University, 3215 Market Street, 7th Floor, Philadelphia, PA 19104 USA.

Background: Exposure to asbestos causes non-malignant and malignant diseases including asbestosis, lung cancer, and mesothelioma. The modern history of such diseases goes back more than a century.

Main Text: While much is known about the ability of asbestos to cause disease, the carcinogenic mechanism is not yet understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12995-020-00267-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294762PMC

NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.

J Med Biochem 2020 Jan;39(1):91-99

University of Ljubljana, Faculty of Medicine, Institute of Biochemistry, Pharmacogenetics Laboratory, Ljubljana, Slovenia.

Background: This study aimed to investigate the association between NLRP3 rs35829419 and CARD8 rs2043211 polymorphisms and the risk of developing pleural plaques, asbestosis, and malignant mesothelioma (MM), and to study the influence of the interactions between polymorphisms and asbestos exposure on the risk of developing these diseases.

Methods: The case-control study included 416 subjects with pleural plaques, 160 patients with asbestosis, 154 subjects with MM and 149 subjects with no asbestos disease. The NLRP3 rs35829419 and CARD8 rs2043211 polymorphisms were determined using real-time PCR-based methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/jomb-2019-0025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282242PMC
January 2020

Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy.

Cancers (Basel) 2020 Jun 15;12(6). Epub 2020 Jun 15.

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Fluence rate is an effector of photodynamic therapy (PDT) outcome. Lower light fluence rates can conserve tumor perfusion during some illumination protocols for PDT, but then treatment times are proportionally longer to deliver equivalent fluence. Likewise, higher fluence rates can shorten treatment time but may compromise treatment efficacy by inducing blood flow stasis during illumination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061584DOI Listing

Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma.

Cancers (Basel) 2020 Jun 13;12(6). Epub 2020 Jun 13.

Department of Pathology, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada.

Well-differentiated papillary mesothelioma (WDPM) is an uncommon mesothelial proliferation that is most commonly encountered as an incidental finding in the peritoneal cavity. There is controversy in the literature about whether WDPM is a neoplasm or a reactive process and, if neoplastic, whether it is a variant or precursor of epithelial malignant mesothelioma or is a different entity. Using whole exome sequencing of five WDPMs of the peritoneum, we have identified distinct mutations in , , , , , , and shared by WDPM cases but not reported in malignant mesotheliomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061568DOI Listing